Clinical Trials
Below are current clinical trials.
259 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
Our group has explored the use of genomic RNA/phage display libraries derived from primary human malignant melanoma cells as a means of identifying antibody detectable targets on cancer cells (cancer vaccines or antibody guided therapeutics). In this approach, we isolate and affinity-column immobilize the IgG fraction from patient serum before and after immune therapy for melanoma, and expose the immobilized antibodies to bacteriophage expressing approximately 2x109 overlapping cDNA sequences of paired (same patient derived plasma and cancer cells) melanoma genomic RNA. Phage, expressing melanoma cDNA express the proteins/peptides on their capsid are “recognized” by the immobilized antibodies are retained in the column, and subsequently eluted for DNA sequencing. Comparison of the DNA profiles of the eluted phage using pre-immunotherapy and post-immunotherapy patient sera will reveal emergence of new antibodies (post-immunotherapy gain of antibodies) against proteins of potential interest for melanoma targeting. In the current proposal, we hypothesize that reacting COVID serum from patients that have recovered from COVID infection and compare to non-infected self-serum (if available) and control healthy volunteer serum (available in our lab) may identify protein targets that have developed as a result of the COVID infection and could be useful in the development of a COVID vaccine as well as a serologic test for anti-COVID immunity.
-
Rochester, Minn.
The purpose of this study is to obtain a whole blood sample from which DNA will be extracted to study polymorphisms in immune response genes and other geneticvariants that may be associated with an increased risk of disease progression among individuals with infectious diseases of public health importance who are enrolled in qualifying INSIGHT studies.
-
Rochester, Minn.
The purpose of this study is to better understand why patients get infectious complications after colon or rectal surgery by identifying the bacteria present on the skin and within the gastrointestinal tract in both healthy volunteers undergoing a colonoscopy, and in patients undergoing colon and rectal surgery. By comparing the bacteria within these two groups, we will better understand the causes of postoperative infectious complications.
-
Rochester, Minn.
This study is to see if PCR test developed at Mayo Clinic to diagnosis C. Difficile infections is able to predict the risk of recurrent infection.
-
Rochester, Minn.
This project will broadly explore the efficacy of community participation in the design and implementation of an intervention to improve physical activity and nutrition among immigrant and refugee (Hispanic, Somali, Sudanese, Cambodian) families in Rochester, Minnesota
-
Rochester, Minn.
The purpose of this study is to develop an advanced multiparametric liver magnetic resonance elastography (MRE) imaging technology for monitoring hepatic inflammation during direct acting antiviral (DAA) treatment, evaluation risks of severe liver injury, and HCC development.
-
Rochester, Minn., Jacksonville, Fla.
The first aim of this study is to verify that the TCR beta sequencing and curation platforms we will be using are able to identify patients with severe COVID-19 based on the TCR repertoires. This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting with severe COVID-19. This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ImmuneCODE Open Access Database to confirm previously published data (PMID: 34253751). Both procedures will be performed by the company that created both platforms, Adaptive Biothechnologies.
The second aim of this study is to sequence the TCR receptors of participating patients and identify TCR motifs that may indicate a predisposition to (or protection from) severe SARS-CoV-2, leading to possible risk stratification of such patients, and whether or not age, gender or ethnicity has any contribution to said risk. This may require that we examine all three cohorts listed in the Subject Information section.
The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those that have been exposed.
-
Jacksonville, Fla.
This Registry is designed to provide long term clinical and virologic follow up in subjects who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored Hepatitis C Virus (HCV) study. This long term follow up study is observational and no treatment is provided for HCV.
-
Scottsdale/Phoenix, Ariz.
The purpose of this study is to identify, recruit, and enroll patients with community-acquired pneumonia (CAP) to collect their blood, sputum, urine, and a nasopharyngeal swab for specimen storage. The study also aims to develop a biomarker assay to detect circulating antigen in patients infected with Coccidioides.
-
Rochester, Minn.
The primary purpose of this study is to evaluate the ability of patients, who are not healthcare workers (HCWs) and have no prior training in swab collection, to collect, package, and ship their own self-collected MT swab specimens (both commercial and Mayo Clinic 3-D printed versions) by following written instructions.